Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities:
Net loss	$ (24,417,000)	$ (25,140,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,177,000	2,062,000
Amortization of discount on investments, net	(87,000)	(144,000)
Stock-based compensation	4,116,000	2,647,000
Non-cash interest expense related to sale of future royalties	804,000	178,000
Non-cash revenue related to sale of future royalties	(3,007,000)	(20,000)
Change in operating assets and liabilities:
Accounts receivable	2,452,000	(244,000)
Prepaid expenses and other assets	(4,240,000)	1,067,000
Accounts payable	2,314,000	(270,000)
Deferred grant revenue	0	(397,000)
Other accrued liabilities	(1,303,000)	(4,199,000)
Net cash used in operating activities	(21,191,000)	(24,460,000)
Cash flows from investing activities:
Purchases of property and equipment	(131,000)	(1,239,000)
Purchases of investments	(9,893,000)	0
Proceeds from maturities of investments	5,000,000	26,700,000
Net cash (used in) provided by investing activities	(5,024,000)	25,461,000
Cash flows from financing activities:
Proceeds from issuance of common stock upon exercise of stock options	7,000	0
Shares acquired to settle employee tax withholding liabilities	(182,000)	(10,000)
Net cash provided by financing activities	18,195,000	1,420,000
Net (decrease) increase in cash, cash equivalents and restricted cash	(8,020,000)	2,421,000
Cash, cash equivalents and restricted cash at beginning of the period	34,755,000	46,013,000
Cash, cash equivalents and restricted cash at end of the period	26,735,000	48,434,000
Supplemental reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets:
Cash and cash equivalents	26,735,000	46,831,000
Restricted cash	0	1,603,000
Cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows at the end of the period	26,735,000	48,434,000
Supplemental disclosure of non-cash investing and financing activity:
Operating lease liabilities arising from obtaining right-of-use assets	0	296,000
Acquisition of property and equipment included in accounts payable and accrued expenses	151,000	246,000
At-the-market Facility [Member]
Cash flows from financing activities:
Net proceeds from issuance of common stock	8,425,000	1,430,000
RA Capital Healthcare Fund 2024 [Member]
Cash flows from financing activities:
Net proceeds from issuance of common stock	$ 9,945,000	$ 0